By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Tisotumab vedotin
Miscellaneous antineoplastics

Tisotumab vedotin

https://themeditary.com/drug/tisotumab-vedotin-7649.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Aug 16, 2023  Additional Content by TheMediTary.Com

Generic name: tisotumab vedotin [ tye-sot-ue-mab-ve-doe-tin ]

Drug class: Miscellaneous antineoplastics

Dosage form: intravenous powder for injection (tftv 40 mg)

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Tivdak, Tisotumab vedotin-tftv (monograph)

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Tisotumab vedotin?

Tisotumab vedotin is used to treat cervical cancer that has spread to other parts of the body (metastatic) after other treatments did not work or stopped working.

Tisotumab vedotin may also be used for purposes not listed in this medication guide.

Warnings

Using tisotumab vedotin can cause changes to the surface of your eye and in some cases may cause serious eye problems including vision loss. Tell your doctor if you have eye redness, dryness, or irritation, or if you notice vision changes or white patches on your eyes.

An eye doctor will need to check your eyes before and during treatment with tisotumab vedotin. You will also need to use prescription eye medications each time you receive a tisotumab vedotin infusion. Be sure to bring all eye medications with you to each infusion appointment.

How should I take Tisotumab vedotin

Tisotumab vedotin is injected into a vein by a healthcare provider.

This medicine must be given slowly over 30 minutes.

Tisotumab vedotin is usually given once every 3 weeks until your body no longer responds to the medication or you have certain side effects.

Using tisotumab vedotin can cause changes to the surface of your eye and in some cases may cause serious eye problems including vision loss. An eye doctor will need to check your eyes before and during treatment with tisotumab vedotin.

You will be given 3 different eye medications to use: steroid eyedrops, vasoconstrictor eyedrops, and lubricating eyedrops. You will need to have all eye medications with you each time you receive a tisotumab vedotin infusion.

  • The steroid eye medication is used before each infusion and continued for 72 hours.

  • The vasoconstrictor eye medication is given just before the infusion.

  • Lubricating eye drops should be used the entire time you are receiving tisotumab vedotin and for 30 days after your last dose.

Do not wear contact lenses while receiving tisotumab vedotin, unless your eye doctor tells you to.

Dosing information

Usual Adult Dose for Cervical Cancer:

2 mg/kg (up to a maximum of 200 mg for patients 100 kg or greater) IV over 30 minutes every 3 weeks until disease progression or unacceptable toxicity

Premedication and Eye Care:
-Conduct an ophthalmic exam including visual acuity and slit lamp exam at baseline, prior to each dose, and as indicated.
-The initial prescription and all renewals of any corticosteroid medications should be made only after examination with a slit lamp.
-Administer the first drop in each eye prior to each infusion; continue to administer the drops in each eye 72 hours after each infusion.
-Administer topical ocular vasoconstrictor drops in each eye immediately prior to each infusion.
-Use cooling eye pads during the infusion.
-Administer topical lubricating eye drops for the duration of therapy and for 30 days after the last dose.
-Advise patients to avoid wearing contact lenses unless advised by their eye care provider for the entire duration of therapy.

Use: For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy

Detailed Tisotumab vedotin dosage information
Tisotumab vedotin Dosage information (more detail)

Before Taking

Tell your doctor if you have ever had:

  • vision or eye problems;

  • bleeding problems;

  • liver disease; or

  • numbness or tingling (neuropathy) in your hands and feet.

Tisotumab vedotin can harm an unborn baby if the mother or the father is using tisotumab vedotin.

  • If you are a woman, you may need a pregnancy test to make sure you are not pregnant. Use birth control while using this medicine and for at least 2 months after your last dose.

  • If you are a man, use birth control if your sex partner is able to get pregnant. Keep using birth control for at least 4 months after your last dose.

  • Tell your doctor right away if a pregnancy occurs.

This medicine may affect fertility (ability to have children) in men. However, it is important to use birth control to prevent pregnancy because tisotumab vedotin can harm an unborn baby.

Do not breastfeed while using this medicine, and for at least 3 weeks after your last dose.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your tisotumab vedotin injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while using Tisotumab vedotin?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Tisotumab vedotin side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Tisotumab vedotin may cause serious side effects. Call your doctor at once if you have:

  • new or worsening vision changes;

  • eye redness, dryness, or irritation;

  • white or red patches on the surface of your eye;

  • new or worsening cough, trouble breathing;

  • stomach cramps, bloating, nausea, vomiting, severe constipation;

  • nosebleeds, blood in your urine, abnormal vaginal bleeding, any bleeding that will not stop;

  • nerve problems--numbness, tingling, pain, burning sensation in your hands or feet, weakness;

  • low hemoglobin (red blood cells)--pale skin, weakness, feeling tired or short of breath, fast heartbeats; or

  • low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of tisotumab vedotin may include:

  • dry eyes;

  • fever, low red or white blood cells;

  • nausea, diarrhea;

  • feeling tired;

  • nosebleeds;

  • numbness or tingling;

  • hair loss;

  • rash; or

  • abnormal kidney function or blood-clotting tests.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See more: Tisotumab vedotin Side Effects

What other drugs will affect Tisotumab vedotin?

Other drugs may affect tisotumab vedotin, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

More about Tisotumab vedotin (Tisotumab vedotin [ tye-sot-ue-mab-ve-doe-tin ])

Dosage information
Tisotumab vedotin Side Effects
During pregnancy
Drug images
Side effects
Breastfeeding Warnings
Drug class: Miscellaneous antineoplastics

Related treatment guides

Cervical Cancer
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by